世界の良性前立腺肥大症市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Benign Prostatic Hyperplasia Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z0741 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、99ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥546,000 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥819,000 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,092,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、良性前立腺肥大症のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（薬物療法、透析、その他）、用途別市場規模（病院、クリニック）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・良性前立腺肥大症の市場動向 ・企業の競争状況、市場シェア ・良性前立腺肥大症の種類別市場規模（薬物療法、透析、その他） ・良性前立腺肥大症の用途別市場規模（病院、クリニック） ・良性前立腺肥大症の北米市場規模2016-2027（アメリカ、カナダ） ・良性前立腺肥大症のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・良性前立腺肥大症のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・良性前立腺肥大症の中南米市場規模2016-2027（メキシコ、ブラジル） ・良性前立腺肥大症の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Abbott、Allergan、Astellas Pharma、Boehringer Ingelheim Pharma、Eli Lilly and Company、GlaxoSmithKline、Merck、Pfizer、Sanofi） ・結論

Benign prostatic hyperplasia (BPH) also known as benign prostatic hypertrophy is characterized by the unusual propagation of the prostatic cells, which causes difficulties like urinary retention and infections of the urinary tract. It is most common among the aging men population, primarily driving this market. On the basis of geographical analysis, the North American region is expected to retain its dominance in this market owing to better healthcare infrastructure, high healthcare expenditure on urological disorders, increased awareness in the society increasing the outpatients center and hospitals visits.

Market Analysis and Insights: Global Benign Prostatic Hyperplasia Market
The global Benign Prostatic Hyperplasia market size is projected to reach US$ 13980 million by 2026, from US$ 10020 million in 2019, at a CAGR of 4.8% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Benign Prostatic Hyperplasia market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Benign Prostatic Hyperplasia market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Benign Prostatic Hyperplasia market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Benign Prostatic Hyperplasia market.

Global Benign Prostatic Hyperplasia Scope and Market Size
Benign Prostatic Hyperplasia market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Benign Prostatic Hyperplasia market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Drug Therapy
Dialysis
Other

Segment by Application
Hospitals
Clinics

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Abbott
Allergan
Astellas Pharma
Boehringer Ingelheim Pharma
Eli Lilly and Company
GlaxoSmithKline
Merck
Pfizer
Sanofi

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Benign Prostatic Hyperplasia Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Drug Therapy
1.2.3 Dialysis
1.2.4 Other
1.3 Market by Application
1.3.1 Global Benign Prostatic Hyperplasia Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinics
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Benign Prostatic Hyperplasia Market Perspective (2016-2027)
2.2 Benign Prostatic Hyperplasia Growth Trends by Regions
2.2.1 Benign Prostatic Hyperplasia Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Benign Prostatic Hyperplasia Historic Market Share by Regions (2016-2021)
2.2.3 Benign Prostatic Hyperplasia Forecasted Market Size by Regions (2022-2027)
2.3 Benign Prostatic Hyperplasia Industry Dynamic
2.3.1 Benign Prostatic Hyperplasia Market Trends
2.3.2 Benign Prostatic Hyperplasia Market Drivers
2.3.3 Benign Prostatic Hyperplasia Market Challenges
2.3.4 Benign Prostatic Hyperplasia Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Benign Prostatic Hyperplasia Players by Revenue
3.1.1 Global Top Benign Prostatic Hyperplasia Players by Revenue (2016-2021)
3.1.2 Global Benign Prostatic Hyperplasia Revenue Market Share by Players (2016-2021)
3.2 Global Benign Prostatic Hyperplasia Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Benign Prostatic Hyperplasia Revenue
3.4 Global Benign Prostatic Hyperplasia Market Concentration Ratio
3.4.1 Global Benign Prostatic Hyperplasia Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Benign Prostatic Hyperplasia Revenue in 2020
3.5 Benign Prostatic Hyperplasia Key Players Head office and Area Served
3.6 Key Players Benign Prostatic Hyperplasia Product Solution and Service
3.7 Date of Enter into Benign Prostatic Hyperplasia Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Benign Prostatic Hyperplasia Breakdown Data by Type
4.1 Global Benign Prostatic Hyperplasia Historic Market Size by Type (2016-2021)
4.2 Global Benign Prostatic Hyperplasia Forecasted Market Size by Type (2022-2027)

5 Benign Prostatic Hyperplasia Breakdown Data by Application
5.1 Global Benign Prostatic Hyperplasia Historic Market Size by Application (2016-2021)
5.2 Global Benign Prostatic Hyperplasia Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Benign Prostatic Hyperplasia Market Size (2016-2027)
6.2 North America Benign Prostatic Hyperplasia Market Size by Type
6.2.1 North America Benign Prostatic Hyperplasia Market Size by Type (2016-2021)
6.2.2 North America Benign Prostatic Hyperplasia Market Size by Type (2022-2027)
6.2.3 North America Benign Prostatic Hyperplasia Market Size by Type (2016-2027)
6.3 North America Benign Prostatic Hyperplasia Market Size by Application
6.3.1 North America Benign Prostatic Hyperplasia Market Size by Application (2016-2021)
6.3.2 North America Benign Prostatic Hyperplasia Market Size by Application (2022-2027)
6.3.3 North America Benign Prostatic Hyperplasia Market Size by Application (2016-2027)
6.4 North America Benign Prostatic Hyperplasia Market Size by Country
6.4.1 North America Benign Prostatic Hyperplasia Market Size by Country (2016-2021)
6.4.2 North America Benign Prostatic Hyperplasia Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Benign Prostatic Hyperplasia Market Size (2016-2027)
7.2 Europe Benign Prostatic Hyperplasia Market Size by Type
7.2.1 Europe Benign Prostatic Hyperplasia Market Size by Type (2016-2021)
7.2.2 Europe Benign Prostatic Hyperplasia Market Size by Type (2022-2027)
7.2.3 Europe Benign Prostatic Hyperplasia Market Size by Type (2016-2027)
7.3 Europe Benign Prostatic Hyperplasia Market Size by Application
7.3.1 Europe Benign Prostatic Hyperplasia Market Size by Application (2016-2021)
7.3.2 Europe Benign Prostatic Hyperplasia Market Size by Application (2022-2027)
7.3.3 Europe Benign Prostatic Hyperplasia Market Size by Application (2016-2027)
7.4 Europe Benign Prostatic Hyperplasia Market Size by Country
7.4.1 Europe Benign Prostatic Hyperplasia Market Size by Country (2016-2021)
7.4.2 Europe Benign Prostatic Hyperplasia Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Benign Prostatic Hyperplasia Market Size (2016-2027)
8.2 Asia-Pacific Benign Prostatic Hyperplasia Market Size by Type
8.2.1 Asia-Pacific Benign Prostatic Hyperplasia Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Benign Prostatic Hyperplasia Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Benign Prostatic Hyperplasia Market Size by Type (2016-2027)
8.3 Asia-Pacific Benign Prostatic Hyperplasia Market Size by Application
8.3.1 Asia-Pacific Benign Prostatic Hyperplasia Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Benign Prostatic Hyperplasia Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Benign Prostatic Hyperplasia Market Size by Application (2016-2027)
8.4 Asia-Pacific Benign Prostatic Hyperplasia Market Size by Region
8.4.1 Asia-Pacific Benign Prostatic Hyperplasia Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Benign Prostatic Hyperplasia Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Benign Prostatic Hyperplasia Market Size (2016-2027)
9.2 Latin America Benign Prostatic Hyperplasia Market Size by Type
9.2.1 Latin America Benign Prostatic Hyperplasia Market Size by Type (2016-2021)
9.2.2 Latin America Benign Prostatic Hyperplasia Market Size by Type (2022-2027)
9.2.3 Latin America Benign Prostatic Hyperplasia Market Size by Type (2016-2027)
9.3 Latin America Benign Prostatic Hyperplasia Market Size by Application
9.3.1 Latin America Benign Prostatic Hyperplasia Market Size by Application (2016-2021)
9.3.2 Latin America Benign Prostatic Hyperplasia Market Size by Application (2022-2027)
9.3.3 Latin America Benign Prostatic Hyperplasia Market Size by Application (2016-2027)
9.4 Latin America Benign Prostatic Hyperplasia Market Size by Country
9.4.1 Latin America Benign Prostatic Hyperplasia Market Size by Country (2016-2021)
9.4.2 Latin America Benign Prostatic Hyperplasia Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Benign Prostatic Hyperplasia Market Size (2016-2027)
10.2 Middle East & Africa Benign Prostatic Hyperplasia Market Size by Type
10.2.1 Middle East & Africa Benign Prostatic Hyperplasia Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Benign Prostatic Hyperplasia Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Benign Prostatic Hyperplasia Market Size by Type (2016-2027)
10.3 Middle East & Africa Benign Prostatic Hyperplasia Market Size by Application
10.3.1 Middle East & Africa Benign Prostatic Hyperplasia Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Benign Prostatic Hyperplasia Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Benign Prostatic Hyperplasia Market Size by Application (2016-2027)
10.4 Middle East & Africa Benign Prostatic Hyperplasia Market Size by Country
10.4.1 Middle East & Africa Benign Prostatic Hyperplasia Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Benign Prostatic Hyperplasia Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Abbott
11.1.1 Abbott Company Details
11.1.2 Abbott Business Overview
11.1.3 Abbott Benign Prostatic Hyperplasia Introduction
11.1.4 Abbott Revenue in Benign Prostatic Hyperplasia Business (2016-2021)
11.1.5 Abbott Recent Development
11.2 Allergan
11.2.1 Allergan Company Details
11.2.2 Allergan Business Overview
11.2.3 Allergan Benign Prostatic Hyperplasia Introduction
11.2.4 Allergan Revenue in Benign Prostatic Hyperplasia Business (2016-2021)
11.2.5 Allergan Recent Development
11.3 Astellas Pharma
11.3.1 Astellas Pharma Company Details
11.3.2 Astellas Pharma Business Overview
11.3.3 Astellas Pharma Benign Prostatic Hyperplasia Introduction
11.3.4 Astellas Pharma Revenue in Benign Prostatic Hyperplasia Business (2016-2021)
11.3.5 Astellas Pharma Recent Development
11.4 Boehringer Ingelheim Pharma
11.4.1 Boehringer Ingelheim Pharma Company Details
11.4.2 Boehringer Ingelheim Pharma Business Overview
11.4.3 Boehringer Ingelheim Pharma Benign Prostatic Hyperplasia Introduction
11.4.4 Boehringer Ingelheim Pharma Revenue in Benign Prostatic Hyperplasia Business (2016-2021)
11.4.5 Boehringer Ingelheim Pharma Recent Development
11.5 Eli Lilly and Company
11.5.1 Eli Lilly and Company Company Details
11.5.2 Eli Lilly and Company Business Overview
11.5.3 Eli Lilly and Company Benign Prostatic Hyperplasia Introduction
11.5.4 Eli Lilly and Company Revenue in Benign Prostatic Hyperplasia Business (2016-2021)
11.5.5 Eli Lilly and Company Recent Development
11.6 GlaxoSmithKline
11.6.1 GlaxoSmithKline Company Details
11.6.2 GlaxoSmithKline Business Overview
11.6.3 GlaxoSmithKline Benign Prostatic Hyperplasia Introduction
11.6.4 GlaxoSmithKline Revenue in Benign Prostatic Hyperplasia Business (2016-2021)
11.6.5 GlaxoSmithKline Recent Development
11.7 Merck
11.7.1 Merck Company Details
11.7.2 Merck Business Overview
11.7.3 Merck Benign Prostatic Hyperplasia Introduction
11.7.4 Merck Revenue in Benign Prostatic Hyperplasia Business (2016-2021)
11.7.5 Merck Recent Development
11.8 Pfizer
11.8.1 Pfizer Company Details
11.8.2 Pfizer Business Overview
11.8.3 Pfizer Benign Prostatic Hyperplasia Introduction
11.8.4 Pfizer Revenue in Benign Prostatic Hyperplasia Business (2016-2021)
11.8.5 Pfizer Recent Development
11.9 Sanofi
11.9.1 Sanofi Company Details
11.9.2 Sanofi Business Overview
11.9.3 Sanofi Benign Prostatic Hyperplasia Introduction
11.9.4 Sanofi Revenue in Benign Prostatic Hyperplasia Business (2016-2021)
11.9.5 Sanofi Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Benign Prostatic Hyperplasia Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Drug Therapy
Table 3. Key Players of Dialysis
Table 4. Key Players of Other
Table 5. Global Benign Prostatic Hyperplasia Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Benign Prostatic Hyperplasia Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Benign Prostatic Hyperplasia Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Benign Prostatic Hyperplasia Market Share by Regions (2016-2021)
Table 9. Global Benign Prostatic Hyperplasia Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Benign Prostatic Hyperplasia Market Share by Regions (2022-2027)
Table 11. Benign Prostatic Hyperplasia Market Trends
Table 12. Benign Prostatic Hyperplasia Market Drivers
Table 13. Benign Prostatic Hyperplasia Market Challenges
Table 14. Benign Prostatic Hyperplasia Market Restraints
Table 15. Global Benign Prostatic Hyperplasia Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Benign Prostatic Hyperplasia Market Share by Players (2016-2021)
Table 17. Global Top Benign Prostatic Hyperplasia Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Benign Prostatic Hyperplasia as of 2020)
Table 18. Ranking of Global Top Benign Prostatic Hyperplasia Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Benign Prostatic Hyperplasia Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Benign Prostatic Hyperplasia Product Solution and Service
Table 22. Date of Enter into Benign Prostatic Hyperplasia Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Benign Prostatic Hyperplasia Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Benign Prostatic Hyperplasia Revenue Market Share by Type (2016-2021)
Table 26. Global Benign Prostatic Hyperplasia Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Benign Prostatic Hyperplasia Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Benign Prostatic Hyperplasia Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Benign Prostatic Hyperplasia Revenue Market Share by Application (2016-2021)
Table 30. Global Benign Prostatic Hyperplasia Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Benign Prostatic Hyperplasia Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Benign Prostatic Hyperplasia Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Benign Prostatic Hyperplasia Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Benign Prostatic Hyperplasia Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Benign Prostatic Hyperplasia Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Benign Prostatic Hyperplasia Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Benign Prostatic Hyperplasia Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Benign Prostatic Hyperplasia Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Benign Prostatic Hyperplasia Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Benign Prostatic Hyperplasia Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Benign Prostatic Hyperplasia Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Benign Prostatic Hyperplasia Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Benign Prostatic Hyperplasia Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Benign Prostatic Hyperplasia Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Benign Prostatic Hyperplasia Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Benign Prostatic Hyperplasia Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Benign Prostatic Hyperplasia Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Benign Prostatic Hyperplasia Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Benign Prostatic Hyperplasia Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Benign Prostatic Hyperplasia Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Benign Prostatic Hyperplasia Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Benign Prostatic Hyperplasia Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Benign Prostatic Hyperplasia Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Benign Prostatic Hyperplasia Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Benign Prostatic Hyperplasia Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Benign Prostatic Hyperplasia Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Benign Prostatic Hyperplasia Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Benign Prostatic Hyperplasia Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Benign Prostatic Hyperplasia Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Benign Prostatic Hyperplasia Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Benign Prostatic Hyperplasia Market Size by Country (2022-2027) & (US$ Million)
Table 62. Abbott Company Details
Table 63. Abbott Business Overview
Table 64. Abbott Benign Prostatic Hyperplasia Product
Table 65. Abbott Revenue in Benign Prostatic Hyperplasia Business (2016-2021) & (US$ Million)
Table 66. Abbott Recent Development
Table 67. Allergan Company Details
Table 68. Allergan Business Overview
Table 69. Allergan Benign Prostatic Hyperplasia Product
Table 70. Allergan Revenue in Benign Prostatic Hyperplasia Business (2016-2021) & (US$ Million)
Table 71. Allergan Recent Development
Table 72. Astellas Pharma Company Details
Table 73. Astellas Pharma Business Overview
Table 74. Astellas Pharma Benign Prostatic Hyperplasia Product
Table 75. Astellas Pharma Revenue in Benign Prostatic Hyperplasia Business (2016-2021) & (US$ Million)
Table 76. Astellas Pharma Recent Development
Table 77. Boehringer Ingelheim Pharma Company Details
Table 78. Boehringer Ingelheim Pharma Business Overview
Table 79. Boehringer Ingelheim Pharma Benign Prostatic Hyperplasia Product
Table 80. Boehringer Ingelheim Pharma Revenue in Benign Prostatic Hyperplasia Business (2016-2021) & (US$ Million)
Table 81. Boehringer Ingelheim Pharma Recent Development
Table 82. Eli Lilly and Company Company Details
Table 83. Eli Lilly and Company Business Overview
Table 84. Eli Lilly and Company Benign Prostatic Hyperplasia Product
Table 85. Eli Lilly and Company Revenue in Benign Prostatic Hyperplasia Business (2016-2021) & (US$ Million)
Table 86. Eli Lilly and Company Recent Development
Table 87. GlaxoSmithKline Company Details
Table 88. GlaxoSmithKline Business Overview
Table 89. GlaxoSmithKline Benign Prostatic Hyperplasia Product
Table 90. GlaxoSmithKline Revenue in Benign Prostatic Hyperplasia Business (2016-2021) & (US$ Million)
Table 91. GlaxoSmithKline Recent Development
Table 92. Merck Company Details
Table 93. Merck Business Overview
Table 94. Merck Benign Prostatic Hyperplasia Product
Table 95. Merck Revenue in Benign Prostatic Hyperplasia Business (2016-2021) & (US$ Million)
Table 96. Merck Recent Development
Table 97. Pfizer Company Details
Table 98. Pfizer Business Overview
Table 99. Pfizer Revenue in Benign Prostatic Hyperplasia Business (2016-2021) & (US$ Million)
Table 100. Pfizer Recent Development
Table 101. Sanofi Company Details
Table 102. Sanofi Business Overview
Table 103. Sanofi Benign Prostatic Hyperplasia Product
Table 104. Sanofi Revenue in Benign Prostatic Hyperplasia Business (2016-2021) & (US$ Million)
Table 105. Sanofi Recent Development
Table 106. Research Programs/Design for This Report
Table 107. Key Data Information from Secondary Sources
Table 108. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Benign Prostatic Hyperplasia Market Share by Type: 2020 VS 2027
Figure 2. Drug Therapy Features
Figure 3. Dialysis Features
Figure 4. Other Features
Figure 5. Global Benign Prostatic Hyperplasia Market Share by Application: 2020 VS 2027
Figure 6. Hospitals Case Studies
Figure 7. Clinics Case Studies
Figure 8. Benign Prostatic Hyperplasia Report Years Considered
Figure 9. Global Benign Prostatic Hyperplasia Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 10. Global Benign Prostatic Hyperplasia Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global Benign Prostatic Hyperplasia Market Share by Regions: 2020 VS 2027
Figure 12. Global Benign Prostatic Hyperplasia Market Share by Regions (2022-2027)
Figure 13. Global Benign Prostatic Hyperplasia Market Share by Players in 2020
Figure 14. Global Top Benign Prostatic Hyperplasia Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Benign Prostatic Hyperplasia as of 2020
Figure 15. The Top 10 and 5 Players Market Share by Benign Prostatic Hyperplasia Revenue in 2020
Figure 16. Global Benign Prostatic Hyperplasia Revenue Market Share by Type (2016-2021)
Figure 17. Global Benign Prostatic Hyperplasia Revenue Market Share by Type (2022-2027)
Figure 18. North America Benign Prostatic Hyperplasia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 19. North America Benign Prostatic Hyperplasia Market Share by Type (2016-2027)
Figure 20. North America Benign Prostatic Hyperplasia Market Share by Application (2016-2027)
Figure 21. North America Benign Prostatic Hyperplasia Market Share by Country (2016-2027)
Figure 22. United States Benign Prostatic Hyperplasia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Canada Benign Prostatic Hyperplasia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe Benign Prostatic Hyperplasia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Benign Prostatic Hyperplasia Market Share by Type (2016-2027)
Figure 26. Europe Benign Prostatic Hyperplasia Market Share by Application (2016-2027)
Figure 27. Europe Benign Prostatic Hyperplasia Market Share by Country (2016-2027)
Figure 28. Germany Benign Prostatic Hyperplasia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. France Benign Prostatic Hyperplasia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. U.K. Benign Prostatic Hyperplasia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Italy Benign Prostatic Hyperplasia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Russia Benign Prostatic Hyperplasia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Nordic Benign Prostatic Hyperplasia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Asia-Pacific Benign Prostatic Hyperplasia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Benign Prostatic Hyperplasia Market Share by Type (2016-2027)
Figure 36. Asia-Pacific Benign Prostatic Hyperplasia Market Share by Application (2016-2027)
Figure 37. Asia-Pacific Benign Prostatic Hyperplasia Market Share by Region (2016-2027)
Figure 38. China Benign Prostatic Hyperplasia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Japan Benign Prostatic Hyperplasia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. South Korea Benign Prostatic Hyperplasia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Southeast Asia Benign Prostatic Hyperplasia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. India Benign Prostatic Hyperplasia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Australia Benign Prostatic Hyperplasia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Latin America Benign Prostatic Hyperplasia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Benign Prostatic Hyperplasia Market Share by Type (2016-2027)
Figure 46. Latin America Benign Prostatic Hyperplasia Market Share by Application (2016-2027)
Figure 47. Latin America Benign Prostatic Hyperplasia Market Share by Country (2016-2027)
Figure 48. Mexico Benign Prostatic Hyperplasia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Brazil Benign Prostatic Hyperplasia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Middle East & Africa Benign Prostatic Hyperplasia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Benign Prostatic Hyperplasia Market Share by Type (2016-2027)
Figure 52. Middle East & Africa Benign Prostatic Hyperplasia Market Share by Application (2016-2027)
Figure 53. Middle East & Africa Benign Prostatic Hyperplasia Market Share by Country (2016-2027)
Figure 54. Turkey Benign Prostatic Hyperplasia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Saudi Arabia Benign Prostatic Hyperplasia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. UAE Benign Prostatic Hyperplasia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Abbott Revenue Growth Rate in Benign Prostatic Hyperplasia Business (2016-2021)
Figure 58. Allergan Revenue Growth Rate in Benign Prostatic Hyperplasia Business (2016-2021)
Figure 59. Astellas Pharma Revenue Growth Rate in Benign Prostatic Hyperplasia Business (2016-2021)
Figure 60. Boehringer Ingelheim Pharma Revenue Growth Rate in Benign Prostatic Hyperplasia Business (2016-2021)
Figure 61. Eli Lilly and Company Revenue Growth Rate in Benign Prostatic Hyperplasia Business (2016-2021)
Figure 62. GlaxoSmithKline Revenue Growth Rate in Benign Prostatic Hyperplasia Business (2016-2021)
Figure 63. Merck Revenue Growth Rate in Benign Prostatic Hyperplasia Business (2016-2021)
Figure 64. Pfizer Revenue Growth Rate in Benign Prostatic Hyperplasia Business (2016-2021)
Figure 65. Sanofi Revenue Growth Rate in Benign Prostatic Hyperplasia Business (2016-2021)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed

---